Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Rating Lowered to “Strong Sell” at Wall Street Zen

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday, Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Friday, October 2nd. HC Wainwright initiated coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Wednesday, October 28th. They set a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold”.

Lakewood-Amedex Biotherapeutics Stock Down 28.5%

NASDAQ:LABT opened at $0.39 on Friday. The firm’s fifty day moving average is $1.19. Lakewood-Amedex Biotherapeutics has a one year low of $0.17 and a one year high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. As a group, analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 earnings per share for the current fiscal year.

Lakewood-Amedex Biotherapeutics Company Profile

Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.